Get the Stockscreener App
0.5447
6.41%
-0.0338
Ensysce Biosciences Inc stock is traded at $0.5447, with a volume of 3.31M.
It is down -6.41% in the last 24 hours and up +142.24% over the past month.
Ensysce Biosciences Inc is a clinical-stage biotech company using its proprietary technology platforms to develop safer prescription drugs. The company is developing a new class of powerful, tamper-proof opioids that prevent both drug abuse and overdoses. Its products are anticipated to provide safer options to treat severe pain and assist in preventing deaths caused by opioid abuse, reducing human and economic costs. The company's current development pipeline includes two new drug platforms: an abuse-resistant opioid prodrug technology, the Trypsin Activated Abuse Protection, or the TAAP platform, and an over-dose protection opioid prodrug technology, the Multi-Pill Abuse Resistant, or the MPAR platform. The Company currently operates in one business segment, which is pharmaceuticals.
See More
Previous Close:
$0.5785
Open:
$0.5815
24h Volume:
3.31M
Relative Volume:
0.14
Market Cap:
$8.63M
Revenue:
-
Net Income/Loss:
$-11.28M
P/E Ratio:
-0.00657
EPS:
-82.86
Net Cash Flow:
$-9.78M
1W Performance:
+30.46%
1M Performance:
+142.24%
6M Performance:
-3.49%
1Y Performance:
-45.31%
1-Day Range:
$0.5022
$0.5815
1-Week Range:
$0.4567
$0.8701
52-Week Range:
$0.1412
$2.06
Ensysce Biosciences Inc Stock (ENSC) Company Profile
Name
Ensysce Biosciences Inc
Sector
Industry
Phone
(858) 263-4196
Address
7946 IVANHOE AVENUE, LA JOLLA
Ensysce Biosciences Inc Stock (ENSC) Latest News
Ensysce Biosciences Presenting at Upcoming Meetings - GuruFocus.com
Perceptive Advisors LLC's Strategic Acquisition of Ensysce Biosc - GuruFocus.com
3 Penny Stocks to Watch Now, 10/24/24 - TipRanks
Regeneron Pharmaceuticals (REGN) Stock Drops Amid Market Volatility - GuruFocus.com
Advaxis (ADXS) Sees 112.96% Surge Amid Market Volatility - GuruFocus.com
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
Ensysce Biosciences adjusts quorum requirement for stockholder meetings - Investing.com India
Ensysce Biosciences adjusts quorum requirement for stockholder meetings By Investing.com - Investing.com South Africa
When Will Ensysce Biosciences, Inc. (NASDAQ:ENSC) Breakeven? - Simply Wall St
Ensysce Biosciences Inc (ENSC) presents a great opportunity, but the stock is slightly undervalued - US Post News
ENSC’s Market Quandary: Decoding the Ups and Downs of 2023 - The InvestChronicle
Closing Figures: Ensysce Biosciences Inc (ENSC)’s Negative Finish at 0.17, Down -4.39 - The Dwinnex
Anchoring Your Portfolio: Is ENSC Stock a Safe Harbor? - The InvestChronicle
Ensysce Biosciences Inc (ENSC) Stock: Navigating a Year of Stock Volatility - The InvestChronicle
Market Momentum: Ensysce Biosciences Inc (ENSC) Registers a -14.87 Decrease, Closing at 0.19 - The Dwinnex
ENSC stock touches 52-week low at $0.19 amid market challenges By Investing.com - Investing.com South Africa
ENSC stock touches 52-week low at $0.19 amid market challenges - Investing.com
Ensysce Biosciences Announces Leadership Team’s Participation in the Annual Pain Therapeutics Summit - StockTitan
Ensysce meets Nasdaq requirements, advances pain treatment - Investing.com
Ensysce meets Nasdaq requirements, advances pain treatment By Investing.com - Investing.com Canada
Ensysce Biosciences responds to recent shareholder inquiries - TipRanks
Ensysce Biosciences Provides Shareholder Update, Responds to Recent Shareholder Inquiries - AccessWire
ENSC stock touches 52-week low at $0.23 amid market challenges - Investing.com Canada
ENSC Stock Update: Ensysce Biosciences Inc’s Banking’s Market Struggles and Potential Opportunities - The InvestChronicle
Ratio Analysis: Unpacking Ensysce Biosciences Inc (ENSC)’s Price-to-Cash and Price-to-Free Cash Flow - The Dwinnex
Ensysce Biosciences faces Nasdaq delisting over noncompliance By Investing.com - Investing.com Australia
Ensysce Biosciences faces Nasdaq delisting over noncompliance - Investing.com
Ensysce Biosciences (NASDAQ:ENSC) Stock Quotes, Forecast and News Summary - Benzinga
Ensysce Biosciences Receives Notice from Nasdaq - AccessWire
Ensysce Biosciences, Inc. (NASDAQ:ENSC) Short Interest Update - Defense World
ENSC stock touches 52-week low at $0.31 amid market challenges - Investing.com Canada
Ensysce Biosciences submits Phase 3 study protocol for pain treatment - Investing.com
Ensysce Biosciences submits Phase 3 study protocol for pain treatment By Investing.com - Investing.com Australia
Ensysce Biosciences Submits Phase 3 Protocol to the FDA - AccessWire
Ensysce Biosciences Posts Video Updates from the IASP World Congress on Pain 2024 - AccessWire
Short Interest in Ensysce Biosciences, Inc. (NASDAQ:ENSC) Increases By 3,885.0% - Defense World
ENSC stock touches 52-week low at $0.34 amid market challenges - Investing.com India
Is Ensysce Biosciences Inc (ENSC) worth investing in despite its undervalued state? - US Post News
Market Insight: Ensysce Biosciences Inc (ENSC)’s Notable Drop, Closing at 0.40 - The Dwinnex
Ensysce Biosciences (ENSC) Stock Is Down 30% Today: What's Going On? - MSN
ENSC stock touches 52-week low at $0.36 amid market challenges - Investing.com India
Balance Sheet Breakdown: Ensysce Biosciences Inc (ENSC)’s Debt-to-Equity and Long-Term Debt/Eq Ratios - The Dwinnex
Ensysce Biosciences announces $5M concurrent offering, shares fall - MSN
Ensysce Biosciences secures $5 million from stock sales - Investing.com
SEC Form 424B5 filed by Ensysce Biosciences Inc. - Quantisnow
ENSCEnsysce Biosciences, Inc. Latest Stock News & Market Updates - StockTitan
Ensysce Biosciences Inc Stock (ENSC) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.75%
0.20%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):